Rachelle W Johnson

15PUBLICATIONS
9CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersClinical pharmacology and therapeuticsChild and adolescent development
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 09, 2026
Programmed cell death ligand 1 (PD-L1) inhibition in tumor naïve mice is bone-sparing throughout the lifespan.

|Jun 30, 2025
Abaloparatide increases bone mass without affecting growth of bone-disseminated cancer cells.

Jeremy F Kane, Gwenyth J Joseph, Lawrence A Vecchi

|Jun 22, 2023
Re-Evaluating the Role of PTHrP in Breast Cancer.

Jeremy F Kane, Rachelle W Johnson

|Mar 20, 2023
Select HDAC Inhibitors Enhance Osteolysis and Bone Metastasis Outgrowth but Can Be Mitigated With Bisphosphonate Therapy.

Miranda E Clements, Lauren Holtslander, Joshua R Johnson

|Dec 19, 2022
Sex-Specific Differences in Gsα-Mediated Signaling Downstream of PTH1R Activation by Abaloparatide in Bone.

Srilatha Swami, Joshua Johnson, Lawrence A Vecchi

|Sep 24, 2021
Hypoxia inducible factor signaling in breast tumors controls spontaneous tumor dissemination in a site-specific manner.

Vera M Todd, Lawrence A Vecchi, Miranda E Clements

Pageof 3

Frequent Collaborators

1 joint publications

James Edwards

1 joint publications

Dana Brantley-Sieders

1 joint publications

Megan M Weivoda

1 joint publications

Lauren Himmel